GGrantIndex
← Leaderboards

Yogish C. Kudva

Mayo Clinic Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$6,907,233
Attributed
$25,025,226
Total exposure
7
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $12.7M · FY2009–25
$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,025,226 · 7

By mechanism

UC4$12,653,694 · 1
R01$11,580,967 · 5
U01$790,565 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Hypoglycemia”

Research focus

HypoglycemiaGlycemic ControlTechnologyQuality Of LifeInsulinInsulin-Dependent Diabetes MellitusGlucoseAlgorithmsClinical TrialsGlycosylated Hemoglobin ADiabetes MellitusClinicHyperglycemiaSafetyGlucose MonitorIndexingInnovationDevicesEventBlood Glucose RegulationEffectivenessRandomizedDiabetes ManagementFamily

Grant awards (18)

Care partner-assisted ImplementatiOn of Patch HybrId Closed Loop Insulin Delivery for Older Adults with T1D (COPILOT)$2,345,176
R01 · FY2025 · DK
T1D-DN KPMP Urban Rural (T1D-DN KUR) Recruitment Site$790,565
U01 · FY2025 · DK
Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial$317,984
R01 · FY2025 · DK · contact PI
Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial$333,445
R01 · FY2024 · DK · contact PI
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$239,044
R01 · FY2023 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$565,751
R01 · FY2022 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$638,470
R01 · FY2021 · DK
Automated Glucose Regulation to improve Diabetes Control and Outcomes for Pregnant Women with Type 1 Diabetes and Fetus$751,268
R01 · FY2020 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$657,345
R01 · FY2020 · DK
Automated Glucose Regulation to improve Diabetes Control and Outcomes for Pregnant Women with Type 1 Diabetes and Fetus$755,768
R01 · FY2019 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$660,368
R01 · FY2019 · DK
Automated Glucose Regulation to improve Diabetes Control and Outcomes for Pregnant Women with Type 1 Diabetes and Fetus$813,259
R01 · FY2018 · DK
Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial$12,653,694
UC4 · FY2016 · DK
Integrated approaches to close the loop in type 1 diabetes$717,961
R01 · FY2013 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$747,802
R01 · FY2012 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$631,882
R01 · FY2011 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$689,948
R01 · FY2010 · DK · contact PI
Integrated approaches to close the loop in type 1 diabetes$715,496
R01 · FY2009 · DK · contact PI